WEBER, HANS JOSEF KARL
WEBER, HANS JOSEF KARL
DIPARTIMENTO DI MATEMATICA E APPLICAZIONI "RENATO CACCIOPPOLI"
A note on the range of vector measures
2017 Urbinati, N.; Weber, H.
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
2024 Woodford, R; Mckeown, J; Hoeijmakers, Ll; Mangana, J; Dimitriou, F; Allayous, C; Zaman, F; Aya, F; Marsiglio, J; Goodman, R; Rayson, V; Placzke, J; Kessels, J; Ramalyte, E; Haque, W; Wilson, I; Trojaniello, C; Benannoune, N; Roberts-Thomson, R; Robert, C; Blank, Cu; Dummer, R; Lebbe, C; Haydon, A; Arance, A; Hu-Lieskovan, S; Johnson, Db; Mcarthur, Ga; Rutkowski, P; Neyns, B; Sullivan, Rj; Weber, J; Carlino, Ms; Ascierto, Pa; S, Lo; Long, Gv; Menzies, Am.
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
2024 Kirkwood, Jm; Vecchio, Md; Weber, J; Hoeller, C; Grob, Jj; Mohr, P; Loquai, C; Dutriaux, C; Chiarion-Sileni, V; Mackiewicz, J; Rutkowski, P; Arenberger, P; Quereux, G; Meniawy, Tm; Ascierto, Pa; Menzies, Am; Durani, P; Lobo, M; Campigotto, F; Gastman, B; Long, Gv
Systemic Therapy for Melanoma: ASCO Guideline Update
2023 Seth, R; Agarwala, Ss; Messersmith, H; Alluri, Kc; Ascierto, Pa; Atkins, Mb; Bollin, K; Chacon, M; Davis, N; Faries, Mb; Funchain, P; Gold, Js; Guild, S; Gyorki, De; Kaur, V; Khushalani, Ni; Kirkwood, Jm; Mcquade, Jl; Meyers, Mo; Provenzano, A; Robert, C; Santinami, M; Sehdev, A; Sondak, Vk; Spurrier, G; Swami, U; Truong, Tg; Tsai, Kk; Van Akkooi, A; Weber, J
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
2023 Larkin, J; Del Vecchio, M; Mandala, M; Gogas, H; Arance, Am; Dalle, S; Cowey, Cl; Schenker, M; Grob, Jj; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, Mo; Di Giacomo, Am; Middleton, Mr; Lutzky, J; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, Ag; Fecher, La; Millward, M; Nathan, Pd; Khushalani, Ni; Queirolo, P; Ritchings, C; Lobo, M; Askelson, M; Tang, H; Dolfi, S; Ascierto, Pa; Weber, J.
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition
2023 Ferguson, R; Chat, V; Morales, L; Simpson, D; Monson, Kr; Cohen, E; Zusin, S; Madonna, G; Capone, M; Simeone, E; Pavlick, A; Luke, Jj; Gajewski, Tf; Osman, I; Ascierto, P; Weber, J; Kirchhoff, T.
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial
2023 Kirkwood, Jm; Del Vecchio, M; Weber, J; Hoeller, C; Grob, Jj; Mohr, P; Loquai, C; Dutriaux, C; Chiarion-Sileni, V; Mackiewicz, J; Rutkowski, P; Arenberger, P; Quereux, G; Meniawy, Tm; Ascierto, Pa; Menzies, Am; Durani, P; Lobo, M; Campigotto, F; Gastman, B; Long, Gv
| Titolo | Tipologia | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|---|
| A note on the range of vector measures | 1.1 Articolo in rivista | 2017 | Urbinati, N.; Weber, H. | |
| Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy | 1.1 Articolo in rivista | 2024 | Woodford, R; Mckeown, J; Hoeijmakers, Ll; Mangana, J; Dimitriou, F; Allayous, C; Zaman, F; Aya, F; Marsiglio, J; Goodman, R; Rayson, V; Placzke, J; Kessels, J; Ramalyte, E; Haque, W; Wilson, I; Trojaniello, C; Benannoune, N; Roberts-Thomson, R; Robert, C; Blank, Cu; Dummer, R; Lebbe, C; Haydon, A; Arance, A; Hu-Lieskovan, S; Johnson, Db; Mcarthur, Ga; Rutkowski, P; Neyns, B; Sullivan, Rj; Weber, J; Carlino, Ms; Ascierto, Pa; S, Lo; Long, Gv; Menzies, Am. | |
| Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery | 1.1 Articolo in rivista | 2024 | Kirkwood, Jm; Vecchio, Md; Weber, J; Hoeller, C; Grob, Jj; Mohr, P; Loquai, C; Dutriaux, C; Chiarion-Sileni, V; Mackiewicz, J; Rutkowski, P; Arenberger, P; Quereux, G; Meniawy, Tm; Ascierto, Pa; Menzies, Am; Durani, P; Lobo, M; Campigotto, F; Gastman, B; Long, Gv | |
| Systemic Therapy for Melanoma: ASCO Guideline Update | 1.1 Articolo in rivista | 2023 | Seth, R; Agarwala, Ss; Messersmith, H; Alluri, Kc; Ascierto, Pa; Atkins, Mb; Bollin, K; Chacon, M; Davis, N; Faries, Mb; Funchain, P; Gold, Js; Guild, S; Gyorki, De; Kaur, V; Khushalani, Ni; Kirkwood, Jm; Mcquade, Jl; Meyers, Mo; Provenzano, A; Robert, C; Santinami, M; Sehdev, A; Sondak, Vk; Spurrier, G; Swami, U; Truong, Tg; Tsai, Kk; Van Akkooi, A; Weber, J | |
| Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 | 1.1 Articolo in rivista | 2023 | Larkin, J; Del Vecchio, M; Mandala, M; Gogas, H; Arance, Am; Dalle, S; Cowey, Cl; Schenker, M; Grob, Jj; Chiarion-Sileni, V; Marquez-Rodas, I; Butler, Mo; Di Giacomo, Am; Middleton, Mr; Lutzky, J; de la Cruz-Merino, L; Arenberger, P; Atkinson, V; Hill, Ag; Fecher, La; Millward, M; Nathan, Pd; Khushalani, Ni; Queirolo, P; Ritchings, C; Lobo, M; Askelson, M; Tang, H; Dolfi, S; Ascierto, Pa; Weber, J. | |
| Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition | 1.1 Articolo in rivista | 2023 | Ferguson, R; Chat, V; Morales, L; Simpson, D; Monson, Kr; Cohen, E; Zusin, S; Madonna, G; Capone, M; Simeone, E; Pavlick, A; Luke, Jj; Gajewski, Tf; Osman, I; Ascierto, P; Weber, J; Kirchhoff, T. | |
| Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial | 1.1 Articolo in rivista | 2023 | Kirkwood, Jm; Del Vecchio, M; Weber, J; Hoeller, C; Grob, Jj; Mohr, P; Loquai, C; Dutriaux, C; Chiarion-Sileni, V; Mackiewicz, J; Rutkowski, P; Arenberger, P; Quereux, G; Meniawy, Tm; Ascierto, Pa; Menzies, Am; Durani, P; Lobo, M; Campigotto, F; Gastman, B; Long, Gv |